EUVIMEDEUVIMED entdecken
Crossref

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023

Tanya R Diefenbach-Elstob, Olivia Lay, Tasoula Zakis, Nikita Deshpande, Sally Soppe, Heidi Peck, Saira Hussain, Yi-Mo Deng, Clyde Depat, Kanta Subbarao, Ian G Barr

Communicable Diseases Intelligence · 2025

DOI: 10.33321/cdi.2025.49.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Tanya R Diefenbach-Elstob und 10 weiteren Autor:innen. Beteiligte Einrichtung: WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Influenza, Human, Influenza B virus, Influenza A Virus, H1N1 Subtype.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a record 15,014 human influenza-positive samples during 2023. Viruses were analysed for their antigenic, genetic, and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hens’ eggs for potential use in seasonal influenza virus vaccines. During 2023, influenza A(H1N1)pdm09 and influenza B/Victoria viruses predominated, accounting for 37% and 28% respectively of all viruses received, compared to 12% for influenza A(H3N2). The majority of A(H1N1)pdm09, A(H3N2) and influenza B viruses analysed at the Centre were found to be antigenically and genetically similar to the respective WHO recommended vaccine strains for the southern hemisphere in 2023. Of 5,531 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, seven A(H1N1)pdm09 viruses showed highly reduced inhibition against oseltamivir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza B virusInfluenza A Virus, H1N1 SubtypeHumansWorld Health OrganizationAntiviral AgentsInfluenza A Virus, H3N2 SubtypeAustraliaInfluenza VaccinesOseltamivirFemaleAdultMaleAdolescentMiddle AgedYoung AdultChildChild, PreschoolDrug Resistance, ViralAnimalsAgedInfantZanamivir

Stichwörter der Autor:innen

Global Influenza Surveillance and Response SystemWorld Health Organizationannual reportinfluenzalaboratorysurveillance

Substanzen

Antiviral AgentsInfluenza VaccinesOseltamivirZanamivir

Autor:innen und Institutionen

  • WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Victoria, Australia.

Zitieren

APA

Diefenbach-Elstob, T. R., Lay, O., Zakis, T., Deshpande, N., Soppe, S., Peck, H., Hussain, S., Deng, Y. M., Depat, C., Subbarao, K., & Barr, I. G. (2025). Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.028

Vancouver

Diefenbach-Elstob TR, Lay O, Zakis T, Deshpande N, Soppe S, Peck H, et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.028

BibTeX
@article{DiefenbachElstob2025,
  author = {Diefenbach-Elstob, Tanya R and Lay, Olivia and Zakis, Tasoula and Deshpande, Nikita and Soppe, Sally and Peck, Heidi and Hussain, Saira and Deng, Yi-Mo and Depat, Clyde and Subbarao, Kanta and Barr, Ian G},
  title = {Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023},
  journal = {Communicable Diseases Intelligence},
  year = {2025},
  doi = {10.33321/cdi.2025.49.028}
}
Kostenlos starten →